Web Exclusive: Find a Clinical Trial That's Right for You
July 09, 2009
Web Exclusive: Find a Clinical Trial That's Right for You
July 09, 2009
Web Exclusive: A Q&A with an Extraordinary Healer
June 30, 2009 – Kathy LaTour
Web Exclusive: Types of Kidney Cancer
June 25, 2009 – The American Cancer Society
Web Exclusive: Helpful Advice
June 25, 2009 – Elizabeth Whittington
Web Exclusive: Developing a Strategy
June 25, 2009 – Elizabeth Whittington
Web Exclusive: Searching for New Targets
June 23, 2009 – Elizabeth Whittington
Web Exclusive: When Survivors Should Exercise Caution
June 22, 2009 – Lena Huang
Web Exclusive: Fertility Guidelines Not Meeting Needs of Patients
June 22, 2009 – Elizabeth Whittington
Web Exclusive: A Peaceful Spirit
June 18, 2009 – Toby Bressler, RN, BSN, OCN
Web Exclusive: The Voice on the Other End of the Phone
June 18, 2009 – Dianne Ericson
Excerpt: Stronger
June 17, 2009 – Natalie Flechsig
Web Exclusive: An Infection Out of Nowhere
June 16, 2009
Web Exclusive: Solving a Medical Mystery
June 16, 2009 – Debu Tripathy, MD
Web Exclusive: Clinical Trials for CUP
June 16, 2009
Childhood Cancer Survivorship Programs
June 16, 2009
Chicken Soup for the Soul: The Cancer Book
June 15, 2009 – Kathy LaTour
Improved Care Needed for Patients Receiving Heart-Toxic Drugs
June 15, 2009 – Melissa Weber
Cancer Research Receives Infusion of Federal Funds
June 15, 2009 – Lacey Meyer
Resources
June 09, 2009
P.S. A Word About Implants & Some Unanswered Questions
June 09, 2009 – Kathy LaTour
How to Find a Cancer Trainer
June 09, 2009 – Lena Huang
Smarter Trials for Smarter Drugs
June 09, 2009 – Laura Beil
Sticker Shock
June 09, 2009 – Laura Beil
Resources
June 09, 2009
From Cancer Warrior to Basketball Player
June 09, 2009 – Deirdre Carey
Taking a Closer Look
June 09, 2009 – Karen Patterson
Surgical Strategies
June 09, 2009 – Karen Patterson
Hair Loss Snapshot
June 09, 2009 – Lacey Meyer
Weighing the Techniques
June 09, 2009 – Charlotte Huff
What About CUP Patients?
June 09, 2009 – Katy Human
Hard Times
June 09, 2009 – Joanne Kenen
Reconstruction Do-Overs
June 09, 2009 – Kathy LaTour
Fighting Fatigue
June 09, 2009 – Lena Huang
Disjointed Custody
June 09, 2009 – Charlotte Huff
No I.D.
June 09, 2009 – Katy Human
ASCO Updates
June 09, 2009 – Staff Reports
Interventions Needed to Get Survivors Moving
June 09, 2009 – Lena Huang
The Financial Advocate
June 09, 2009 – Kathy LaTour
Ovarian Cancer Survivors Course
June 09, 2009
Q & A: Prostate Cancer Screening
June 09, 2009 – Len Lichtenfeld, MD
www.armyofwomen.org
June 09, 2009 – Elizabeth Whittington
With a Friend Like Will Ferrell...
June 09, 2009 – Lacey Meyer
Program Keeps Tabs on Childhood Cancer Survivors
June 09, 2009 – Lacey Meyer
Revisiting the Seasons of Survival
June 09, 2009 – Kenneth D. Miller, MD
Prostate, Brain & Kidney Cancers
June 09, 2009 – Elizabeth Whittington
A Life Beyond Cancer
June 09, 2009 – Renée La Forest
Good Grilling
June 09, 2009 – Lena Huang
Medical Devices Face Stricter Regulations
June 09, 2009 – Jo Cavallo
All Is Not Lost
June 09, 2009 – Lacey Meyer
Letters from Our Readers
June 09, 2009
Message from the Editor
June 09, 2009 – Debu Tripathy, MD
Targeted Therapy: Hope or Hype?
June 09, 2009 – Laura Beil
Conquering Cancer & the Classroom
June 09, 2009 – Scott Williams
Reining in Renal Cancer
June 09, 2009 – Karen Patterson
Web Exclusive: Find a Clinical Trial That's Right for You
July 09, 2009
Web Exclusive: Find a Clinical Trial That's Right for You
July 09, 2009
Web Exclusive: A Q&A with an Extraordinary Healer
June 30, 2009 – Kathy LaTour
Web Exclusive: Types of Kidney Cancer
June 25, 2009 – The American Cancer Society
Web Exclusive: Helpful Advice
June 25, 2009 – Elizabeth Whittington
Web Exclusive: Developing a Strategy
June 25, 2009 – Elizabeth Whittington
Web Exclusive: Searching for New Targets
June 23, 2009 – Elizabeth Whittington
Web Exclusive: When Survivors Should Exercise Caution
June 22, 2009 – Lena Huang
Web Exclusive: Fertility Guidelines Not Meeting Needs of Patients
June 22, 2009 – Elizabeth Whittington
Web Exclusive: A Peaceful Spirit
June 18, 2009 – Toby Bressler, RN, BSN, OCN
Web Exclusive: The Voice on the Other End of the Phone
June 18, 2009 – Dianne Ericson
Excerpt: Stronger
June 17, 2009 – Natalie Flechsig
Web Exclusive: An Infection Out of Nowhere
June 16, 2009
Web Exclusive: Solving a Medical Mystery
June 16, 2009 – Debu Tripathy, MD
Web Exclusive: Clinical Trials for CUP
June 16, 2009
Childhood Cancer Survivorship Programs
June 16, 2009
Chicken Soup for the Soul: The Cancer Book
June 15, 2009 – Kathy LaTour
Improved Care Needed for Patients Receiving Heart-Toxic Drugs
June 15, 2009 – Melissa Weber
Cancer Research Receives Infusion of Federal Funds
June 15, 2009 – Lacey Meyer
Resources
June 09, 2009
P.S. A Word About Implants & Some Unanswered Questions
June 09, 2009 – Kathy LaTour
How to Find a Cancer Trainer
June 09, 2009 – Lena Huang
Smarter Trials for Smarter Drugs
June 09, 2009 – Laura Beil
Sticker Shock
June 09, 2009 – Laura Beil
Resources
June 09, 2009
From Cancer Warrior to Basketball Player
June 09, 2009 – Deirdre Carey
Taking a Closer Look
June 09, 2009 – Karen Patterson
Surgical Strategies
June 09, 2009 – Karen Patterson
Hair Loss Snapshot
June 09, 2009 – Lacey Meyer
Weighing the Techniques
June 09, 2009 – Charlotte Huff
What About CUP Patients?
June 09, 2009 – Katy Human
Hard Times
June 09, 2009 – Joanne Kenen
Reconstruction Do-Overs
June 09, 2009 – Kathy LaTour
Fighting Fatigue
June 09, 2009 – Lena Huang
Disjointed Custody
June 09, 2009 – Charlotte Huff
No I.D.
June 09, 2009 – Katy Human
ASCO Updates
June 09, 2009 – Staff Reports
Interventions Needed to Get Survivors Moving
June 09, 2009 – Lena Huang
The Financial Advocate
June 09, 2009 – Kathy LaTour
Ovarian Cancer Survivors Course
June 09, 2009
Q & A: Prostate Cancer Screening
June 09, 2009 – Len Lichtenfeld, MD
www.armyofwomen.org
June 09, 2009 – Elizabeth Whittington
With a Friend Like Will Ferrell...
June 09, 2009 – Lacey Meyer
Program Keeps Tabs on Childhood Cancer Survivors
June 09, 2009 – Lacey Meyer
Revisiting the Seasons of Survival
June 09, 2009 – Kenneth D. Miller, MD
Prostate, Brain & Kidney Cancers
June 09, 2009 – Elizabeth Whittington
A Life Beyond Cancer
June 09, 2009 – Renée La Forest
Good Grilling
June 09, 2009 – Lena Huang
Medical Devices Face Stricter Regulations
June 09, 2009 – Jo Cavallo
All Is Not Lost
June 09, 2009 – Lacey Meyer
Letters from Our Readers
June 09, 2009
Currently Viewing
Message from the Editor
June 09, 2009 – Debu Tripathy, MD
Conquering Cancer & the Classroom
June 09, 2009 – Scott Williams
Reining in Renal Cancer
June 09, 2009 – Karen Patterson

VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Message from the Editor

Have targeted therapies lived up to our expectations?

BY Debu Tripathy, MD
PUBLISHED June 09, 2009

We all have a curious habit of marveling briefly at new technology when it dazzles at center stage, only to take it for granted when it becomes a routine part of life. Whether it’s an automobile, cell phone, or CT scanner, we only tend to notice when it breaks down or fails to perform up to standards.

We are now a little more than a decade out from the debut of molecularly targeted therapies for cancer. Has some of the luster worn off? In this issue’s cover story, “Targeted Therapy: Hope or Hype?" you will see there’s no simple answer to that question.

On one hand, we have seen small stepwise improvements in therapy that have translated into added longevity and higher cure rates in some cases. On the other hand, we are encountering new side effects and the development of resistance to therapy, frustratingly similar to what has been seen with chemotherapy. However, the majority of new drugs in testing for cancer are targeted therapies that have been rationally designed to attack a specific feature of cancer. And they’re safer, with far fewer patients being admitted for treatment side effects compared with one or two decades ago. 

While chemotherapy may injure normal tissue more readily, it also deals cancer cells a more lethal blow since it goes directly after the process of cell division—the main abnormality of cancer, but also a necessary process for normal tissue. Although targeted therapy is more nuanced and more selective for cancer cells than chemotherapy, in most cases, the best results are obtained when the two are combined.

But we’re learning there’s no perfect magic bullet. Many of the pathways we thought were unique to cancer actually turn out to be important for normal cells as well. In nature, many interrelationships are obscure and complex, and such is the case with targeted therapy, where its effects, good and bad, can be hidden. As I write this, a warning letter from the Food and Drug Administration was made public about newly uncovered side effects—holes in the intestine or stomach, blistering skin, and eye ulcers—of Tarceva (erlotinib), a drug approved five years ago for lung cancer and, shortly thereafter, for pancreatic cancer.

Are we becoming disillusioned with targeted therapies? Not quite yet. The biotech industry has more drugs in the pipeline than ever before and the investment community is still supporting more drug innovation and development. Another generation of targeted drugs is addressing cellular pathways that were not even known a few years ago. One of the “newer” targets is mTOR (mammalian target of rapamycin), a central component of several pathways that mediate cell growth and angiogenesis. As outlined in “Reining In Renal Cancer," mTOR inhibitors are now approved for advanced kidney cancer and are in clinical trials for other cancers. 

There are reasons for optimism about targeted drugs despite their sobering limitations. New tools are being rolled out to characterize tumors and define which treatment will work best, and the number of patients in clinical trials and centers offering these trials has grown, meaning less time needed to test and approve drugs.

The revolution of targeted agents is not quite over. There’s still much we need to learn about how to decipher the inner workings of cancer, and how to safely use these agents earlier in the course of treatment, when they may be more effective. At the dawn of a new era in health care policy, targeted therapy for cancer will remain at center stage.

Continue the conversation on CURE’s forum. >>
Talk about this article with other patients, caregivers, and advocates in the CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In